View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 8, 2022

SD Biosensor and SJL Partners to acquire Meridian Bioscience for $1.53bn

The SDB and SJL consortium will fund the deal through cash on hand and additional funding.

A consortium formed by SD Biosensor (SDB) and SJL Partners has signed a definitive merger agreement to acquire diagnostic products manufacturer Meridian Bioscience in an all-cash deal valued at approximately $1.53bn.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

According to the deal terms, the shareholders of Meridian Bioscience will receive $34 per share in cash, which represents a 16% premium based on the one-month average price per share of common stock starting 7 June.

Meridian Bioscience develops, produces, markets and distributes a range of diagnostic products in areas that include upper respiratory infections, gastrointestinal and blood lead level testing.

The company also provides critical life science raw materials that are used in immunological and molecular tests for human and plant applications.

SDB and SJL will fund the transaction through a combination of cash on hand and additional financing.

Meridian CEO Jack Kenny said: “In addition to delivering immediate and significant value to our shareholders, we believe the transaction will enhance our ability to serve customers as we navigate the decline in Covid-19 testing demand and develop new products with the benefit of SDB’s industry expertise and complementary offerings.

“I look forward to working with SDB and SJL and the rest of our Meridian team to build long-term strength and drive further growth in the diagnostics space.”

The transaction is subject to Meridian shareholders’ approval, receipt of required regulatory approvals and other customary closing conditions. It is anticipated to conclude in the fourth calendar quarter of the year.

Once the deal closes, SD Biosensor is expected to hold about 60% of Meridian while the remaining 40% will be held by SJL.

The consortium plans to operate the acquired company as an independent entity, and its leadership team, as well as headquarters, are expected to remain the same.

Last November, Meridian Bioscience secured emergency use authorization (EUA) for its Revogene SARS-CoV-2 assay from the US Food and Drug Administration (FDA).

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network